We report on a case of severe hypoglycemia observed after injection of the somatostatin analog SMS 201-995 in an insulin-dependent diabetic patient connected to an artificial pancreas (Biostator GCIIS). Hypoglycemia occurred in a sudden and unexpected way 23 min after the first SMS injection (50 ug). Details on patient's characteristics and on the peculiar clinical situation in which this complication appeared are given. Furthermore, the possible mechanism(s) responsible for the hypoglycemia are thoroughly discussed. Finally we express a call for caution when administering this drug in insulin-dependent diabetes mellitus.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-2007-1010938 | DOI Listing |
Syst Rev
January 2025
Centre for Clinical Intervention Research, Copenhagen Trial Unit, Capital Region of Denmark, Copenhagen, Denmark.
Background: Type 1 diabetes is a serious, chronic disorder with an increasing incidence among children and adolescents. Glycemic control in individuals with type 1 diabetes is better managed through a basal-bolus regimen with either regular human or rapid-acting insulin analogues administered as a bolus at mealtimes. Rapid-acting insulin analogues have been hypothesized to cause optimal glycemic control and less risk of hypoglycemic episodes compared to regular human insulins.
View Article and Find Full Text PDFAnn Intern Med
January 2025
Mayo Clinic, Rochester, Minnesota, USA (F.L., M.R.G., V.M.M.).
Endocrinology: [Formula: see text].
View Article and Find Full Text PDFCureus
December 2024
Department of Diabetes, Metabolism and Endocrinology, Japan Labor Health and Safety Organization, Tokyo Rosai Hospital, Tokyo, JPN.
Severe hypoglycemia (SH) is a significant risk, particularly in the elderly, and adrenal insufficiency (AI) may be a contributing factor. This study examines six cases of late dumping syndrome (LDS)-induced reactive hypoglycemia (RH), with AI as a potential trigger. Three of the six patients were diagnosed with AI, and one experienced a hypoglycemic coma.
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
Medical Care Center Endocrinology and Diabetology, Düsseldorf, Germany.
Aims: This study assessed efficacy and safety of the fixed ratio combination iGlarLixi 100/33 (insulin glargine 100 U/mL plus lixisenatide 33 μg/mL) in people with type 2 diabetes (PwT2D) in daily clinical practice.
Materials And Methods: This non-interventional, multicentre, prospective, single-arm 24-week study documented PwT2D with an HbA1c of 7.5%-10.
Diabetes Care
January 2025
Allam Diabetes Centre, Hull University Teaching Hospitals National Health Service (NHS) Trust, Hull, U.K.
Objective: This study aimed to explore the relationship between time below range (TBR), impaired awareness of hypoglycemia (IAH), and severe hypoglycemia (SH).
Research Design And Methods: This cross-sectional study analyzed data from individuals with diabetes using continuous glucose monitors (CGMs) in the Association of British Clinical Diabetologists audit. Hypoglycemia awareness was assessed via the Gold score (≥4 denoting IAH), and SH was defined as hypoglycemia requiring third-party assistance.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!